-50%

est. 2Y upside i

HealthcareSeries D+

Rank

#3020

Sector

Biotechnology / Molecular Diagnostics

Est. Liquidity

~3Y

Data Quality

Data: Medium

Inflammatix presents a moderate upside opportunity driven by its innovative, FDA-cleared sepsis diagnostic in a growing market.

Last updated: March 10, 2026

Bull (30%)+100%

Rapid and widespread adoption of the TriVerity test system, driven by strong clinical outcomes and favorable reimbursement, leads to significant market share in the sepsis diagnostics market. Expansion into new indications or international markets pushes the company's valuation to $420M (a 100% increase), resulting in substantial returns for common shareholders.

Base (40%)+20%

Steady but not explosive commercialization of TriVerity, achieving moderate market penetration in emergency departments. The company reaches a valuation of $252M (a 20% increase) through continued private funding or a modest acquisition, allowing common shareholders to realize some return after investor preferences.

Bear (30%)-40%

Slower-than-expected market adoption of TriVerity, coupled with aggressive competition from established players like Roche and Abbott, leads to a down round or acquisition at a valuation of $126M (a 40% decrease). Given $200M in liquidation preferences, common shareholders would receive no proceeds.

Est. time to liquidity~2.5 years

Preference Stack Risk

severe

Funding Intensity

95%

Investors have provided $200M in total funding on a $210M valuation, meaning they hold substantial liquidation preferences that would claim most proceeds in an exit at or below the current valuation.

Dilution Risk

high

Given the high capital intensity and early commercialization stage, further funding rounds are likely needed, which could lead to additional dilution for existing shareholders.

Secondary Liquidity

limited

While platforms like EquityZen and Forge facilitate secondary transactions for accredited investors, active public secondary markets for Inflammatix common stock do not exist.

Questions to Ask at the Interview

Strategic questions based on Inflammatix's data — designed to show you've done your homework.

  • 1

    “Given the strong competitive moat and recent FDA clearance, how is Inflammatix strategizing to rapidly scale commercialization and gain market share against established players like Roche and Abbott in the sepsis diagnostics space?”

  • 2

    “With the company in early commercialization and high capital intensity, what are the key milestones for revenue growth and profitability over the next 24 months, and how will these impact the need for future funding rounds?”

  • 3

    “Considering the Series E funding and the significant liquidation preferences, what is the company's projected timeline and preferred path to a liquidity event (IPO or acquisition), and how does management plan to ensure meaningful returns for common shareholders?”

Community

Valuation Sentiment

Our model estimates -50% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.